News Releases

Updated data across two dose levels of 200 mW/cm and 400 mW/cm in LA-PDAC trial show 71% (5/7) patients resected following VTP with a consistent and well-tolerated safety profile Early clinical observations of Padeliporfin VTP in LA-PDAC support advancement of the program with potential for accelerated registrational pathway, strengthened by robust efficacy and durability data … Continued

Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed Primary Response Evaluation (PRE) Updated durability data shows 85.7% (18/21) of patients who completed the Maintenance Treatment Phase (MTP) sustained CRs in the treated area for at least 12 months as of the data cutoff date … Continued

Company to present updated data from the Phase 3 ENLIGHTED trial of Padeliporn VTP in LG UTUC with topline data expected in 2026 Additional preliminary data from the Phase 1 trial in LA-PDAC to be presented at ASCO; initial data from rst cohort show promising signs of efcacy with a well-tolerated safety prole   TEL … Continued

Initial data from first cohort in LA-PDAC show 66% (2/3) patients resected following VTP at lowest light dose with a consistent and well-tolerated safety profile LA-PDAC program represents large market opportunity in highest unmet need patients, with potential for accelerated registrational pathway; additional results from Phase 1 trial expected in 2026 Topline data from Phase … Continued

Complete response (CR) observed in 70% (35/50) of patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP) Initial durability data shows all patients (100%) who completed the Maintenance Treatment Phase (MTP) sustained CRs in the treated area for at least 12 months as of the data cutoff date Padeliporfin … Continued

TEL AVIV, Israel, Nov. 19, 2025 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced an abstract including updated interim results from ENLIGHTED, the Company’s ongoing Phase 3 study of Padeliporfin VTP treatment of patients with low-grade … Continued

Previously inoperable patient converted to eligible for resection, underwent pancreaticoduodenectomy, following single course of treatment with Padeliporfin VTP –   TEL AVIV, Israel, June 05, 2025 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stagebiotechnology company focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced that the first … Continued

Complete response (CR) observed in 73% (27/37) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP) – Padeliporfin VTP treatment continues to be safe and well-tolerated, establishing profile consistent with prior results alongside additional follow-up in Maintenance Treatment Phase (MTP) – Interim analysis follows evaluation of 50% … Continued

Company to present interim update from ENLIGHTED Phase 3 Study in LG UTUC following assessment of 50% of targeted total evaluable patient enrollment–   TEL AVIV, Israel, May 22, 2025 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnologycompany focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy totreat a range of solid tumors, today announced … Continued

Complete response (CR) observed in 79% (26/33) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP) of the ENLIGHTED Phase 3 trial evaluating Padeliporfin VTP in UTUC – Padeliporfin VTP treatment continues to be safe and efficacious, establishing profile consistent with prior results alongside additional follow-up in … Continued